fbpx

REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search
News

Sheba Study Indicates: Pfizer-BioNTech COVID-19 Vaccine Effective Against Omicron Variant

COVID-19 Vaccine Protects Against Severe Illness
According to a study conducted by Sheba Medical Center and the Israeli Ministry of Health, three doses of the Pfizer-BioNTech COVID-19 vaccine provide significant protection against the Omicron variant.

Following the emergence of the COVID-19 Omicron variant, many wondered if existing vaccines would provide adequate protection. A recent study conducted by Sheba Medical Center and the Israeli Ministry of Health attempted to address concerns.

The study evaluated the efficacy of existing COVID-19 vaccines against the Omicron variant and confirmed that receiving three doses of the Pfizer-BioNTech COVID-19 vaccine will provide significant protection against the Omicron variant, as results indicate that the vaccine prevents severe illness.

In contrast, the study found that two doses of the vaccine are not likely to be effective against the Omicron variant. Thus, an individual vaccinated only twice remains at high risk of contracting the variant and becoming seriously ill.

According to Prof. Gili Regev-Yochay, Head of the Infection Prevention and Control Unit at Sheba, who also led the study: “The findings emphasized the importance of increasing the vaccination rates as an effective and necessary measure to stop the spread of the virus.”

Related
Sheba Leverages ChatGPT
Accelerating Diagnostics: ChatGPT Results Aligned with Breast Cancer Board Recommendations
Recently, several distinguished Sheba clinicians were impressed by the tool’s capabilities. The group, which included Dr. Vera Sorin, Dr. Eyal Klang, Dr. Miri Sklair-Levy, Prof.…
Read More
Sheba and Vidac
Novel Drug Set to Improve CAR T-Cell Therapy Effectiveness
While many medical centers around the world depend on external labs to genetically engineer patient T-cells, a process that can take up to a few…
Read More
Sheba Named Global Oncology Leader
by Newsweek Magazine
Dedicated to providing those in need across the globe ‘Hope Without Boundaries,’ Sheba treats patients from more than 100 countries each year, employing the latest…
Read More